BIYKEM BOZKURT to Adrenergic beta-Antagonists
This is a "connection" page, showing publications BIYKEM BOZKURT has written about Adrenergic beta-Antagonists.
Connection Strength
0.718
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.
Score: 0.179
-
Heart?Failure Drug Treatment-Inertia,?Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart Fail. 2023 01; 11(1):1-14.
Score: 0.169
-
Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure. J Am Coll Cardiol. 2019 05 21; 73(19):2384-2387.
Score: 0.135
-
Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol. 2009 Jul 15; 104(2):270-5.
Score: 0.068
-
Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy. Am J Cardiol. 2008 Nov 15; 102(10):1356-60.
Score: 0.064
-
Prevention of heart failure after acute myocardial infarction. Lancet. 2025 Sep 13; 406(10508):1154-1170.
Score: 0.052
-
An Updated Review on the Role of Non-dihydropyridine Calcium Channel Blockers and Beta-blockers in Atrial Fibrillation and Acute Decompensated Heart Failure: Evidence and Gaps. Cardiovasc Drugs Ther. 2023 12; 37(6):1205-1223.
Score: 0.041
-
Experimental options in the treatment of heart failure: the role of cytokine antagonism. Heart Fail Monit. 2001; 1(4):114-21.
Score: 0.009